HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating for Oruka Therapeutics (NASDAQ:ORKA) and maintained a price target of $45.
October 31, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Oruka Therapeutics, maintaining a $45 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $45 price target by a reputable analyst suggests positive sentiment and confidence in Oruka Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100